TRINETRA › Sectors › Healthcare
Global Health Limited (MEDANTA) — share price, P/E and fundamentals
Global Health Limited (NSE: MEDANTA) closed at ₹1,264.00 on 30 Oct 2026, -7.9% over one year, against a 52-week range of ₹956.00 – ₹1,544.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 30 Jul 2026) it reported revenue of ₹1,304 cr and net profit of ₹159 cr, a 12.2% net margin; revenue grew 26.5% and profit grew 2.5% year on year.
On four consecutive filed quarters its trailing P/E is 61.1; since 15 May 2025 its own P/E has ranged from 50.3 to 79.6 (median 66.1), and today's reading is higher than 26% of those 361 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 16.0%, ROCE 18.2%, debt-to-equity 0.30, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 44% of 63 sector peers; PBT margin higher than 44% of 63 sector peers; ROE higher than 64% of 63 sector peers.
Key figures
| Last close | ₹1,264.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -16.1% / +14.3% / -7.9% |
| 52-week low – high | ₹956.00 – ₹1,544.00 |
| Market capitalisation | ₹33,973 cr |
| Trailing P/E | 61.1 |
| Price / book | 8.58 |
| EV / EBITDA | 33.1 |
| Earnings yield | 1.6% |
| TTM EPS | ₹20.69 |
| TTM net profit | ₹556 cr |
| Quarter revenue | ₹1,304 cr |
| Quarter net profit | ₹159 cr |
| Net margin | 12.2% |
| Revenue growth (YoY) | +26.5% |
| Profit growth (YoY) | +2.5% |
| Return on equity | 16.0% |
| ROCE | 18.2% |
| Debt / equity | 0.30 |
| Current ratio | 2.67 |
| Free cash flow | ₹-124 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹26.1 cr |
Against Healthcare peers
| Metric | MEDANTA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.17 | 12.89 | 44 |
| PBT margin | 16.35 | 17.68 | 44 |
| ROE | 16.03 | 13.86 | 64 |
| ROCE | 18.18 | 16.59 | 59 |
| Debt / equity | 0.30 | 0.11 | 72 |
| Cash conversion | 1.29 | 1.25 | 53 |
| Trailing P/E | 61.08 | 43.07 | 73 |
| P/B | 8.58 | 5.88 | 72 |
Questions
What is the P/E ratio of Global Health Limited?
Global Health Limited's trailing P/E is 61.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 15 May 2025 its P/E has ranged 50.3–79.6.
What were Global Health Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Global Health Limited reported revenue of ₹1,304 cr and net profit of ₹159 cr (consolidated), filed with the exchange on 30 Jul 2026.
What is Global Health Limited's ROE?
Return on equity is 16.0% based on the balance sheet dated 31 Mar 2026.
Does Global Health Limited have debt?
Debt-to-equity is 0.30 on the balance sheet dated 31 Mar 2026.
What is MEDANTA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, MEDANTA traded between ₹956.00 and ₹1,544.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.